A study reported that VA outcomes were similar among the three anti-VEGF drugs, in which bevacizumab use was only considered on a compassionate basis in patients with AMD who did not meet the treatment criteria for ranibizumab or aflibercept use [20]. The gene discussed is VEGFA; the disease is age-related macular degeneration.